Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to -$101.3 million.

  • Foghorn Therapeutics' Free Cash Flow rose 11.51% to -$18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.9 million, marking a year-over-year increase of 14.45%. This contributed to the annual value of -$101.3 million for FY2024, which is 15.10% up from last year.
  • Foghorn Therapeutics' Free Cash Flow amounted to -$101.3 million in FY2024, which was up 15.10% from -$119.3 million recorded in FY2023.
  • Foghorn Therapeutics' 5-year Free Cash Flow high stood at $192.4 million for FY2022, and its period low was -$119.3 million during FY2023.
  • Its 3-year average for Free Cash Flow is -$9.4 million, with a median of -$101.3 million in 2024.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 459.21% in 2022, then slumped by 162.02% in 2023.
  • Over the past 5 years, Foghorn Therapeutics' Free Cash Flow (Yearly) stood at -$47.5 million in 2020, then declined by 12.84% to -$53.6 million in 2021, then surged by 459.21% to $192.4 million in 2022, then slumped by 162.02% to -$119.3 million in 2023, then climbed by 15.10% to -$101.3 million in 2024.